High density-lipoprotein subfractions of patients using cardio-selective beta-blockers

Cardiovascular Drugs and Therapy

Volumn 16, Issue 2, 2002, Pages 127-131

  Kuster, Gabriela M ^a   Amann, Franz Wolfgang ^a   Neuenschwander, Christian ^a   Drexel, Heinz ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Beta adrenergic blockers; Coronary artery disease; High density lipoprotein subfractions; Plasma lipids

Indexed keywords

APOLIPOPROTEIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; MALE; MIDDLE AGED; RADIOGRAPHY; RISK FACTOR; STATISTICAL ANALYSIS; ANGINA PECTORIS; BETA ADRENERGIC RECEPTOR BLOCKING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DYSLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; APOLIPOPROTEINS; ATENOLOL; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DATA INTERPRETATION, STATISTICAL; HUMANS; LIPOPROTEINS, HDL; MALE; METOPROLOL; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES; COMPARATIVE STUDY; HUMAN; LIPOPROTEINS, HDL CHOLESTEROL; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 0035997518     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015753432426     Document Type: Article

References (28)

1. Effects of celiprolol and other antihypertensive agents on serum lipids and lipoproteins
2. Antihypertensive therapy. Taking lipids into consideration
3. Antihypertensive agents, serum lipoproteins and glucose metabolism
4. Beta-blockers, lipids, and coronary atherosclerosis: Fact or fiction?
5. Normalization of lipid metabolism after withdrawal from antihypertensive long-term therapy with beta-blockers and diuretics
6. Adrenergic mechanisms in control of plasma lipid concentrations
7. Lipoprotein lipids in older people. Results from the cardiovascular health study
8. Effect of beta-blockers on blood lipid profile
9. Beta-blockers, plasma lipids, and coronary heart disease
10. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study
11. Quantitation of high-density lipoprotein subclasses after separation by dextran sulfate and Mg 2+ precipitation
12. A dual-precipitation method evaluated for measurement of cholesterol in high-density lipeprotein subfractions HDL2 and HDL3 in human plasma
13. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease
14. Apolipoproteins A I and B in health and metabolic diesease
15. Differentiation of beta-blocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidaemic or dyslipidaemic profiles
16. Atenolol and metoprolol: Comparison of effects on blood pressure and serum lipoproteins, and side effects
17. Effects of pindolol and metoprolol on plasma lipids and lipoproteins
18. Effect of pindolol versus atenolol on lipid profile in hypertensive patients
19. Effect of beta-blockers on plasma lipids
20. Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females
21. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease
22. Effects of doxazosin and propranolol administration on lipoprotein lipases in cholesterol-fed rats
23. Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro
24. HDL metabolism
25. Association of specific overt behaviour pattern with blood and cardiovascular findings
26. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
27. Long-term treatment with metoprolol after myocardial infarction: Effect on 3-year mortality and morbidity
28. Beta-adrenergic blockade for survivors of acute myocardial infarction